NCT05576454 - Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects | Biotech Hunter

Enrollment

207

Participants

Timeline

Start Date

September 20, 2022

Primary Completion Date

May 26, 2023

Study Completion Date

June 19, 2023

Conditions

Severe Asthma

Interventions

DRUG

Mepolizumab Injection (BAT2606 Injection)

In this group, each subject will receive single subcutaneous injection of 100 mg BAT2606 Injection.

DRUG

Mepolizumab Injection (EU-licensed Nucala)

In this group, each subject will receive single subcutaneous injection of 100 mg Mepolizumab Injection (EU-licensed Nucala®).

DRUG

Mepolizumab Injection (US-licensed Nucala)

In this group, each subject will receive single subcutaneous injection of 100 mg Mepolizumab Injection (US-licensed Nucala®).

Trial Locations (1)

The First Hospital of Jilin University, Jilin